Last mentioned: 4d ago
Current Assessment
Industry reports highlight the persistent gap between regulatory goals and technological capabilities.
NAMs Investment Surge
Significant venture capital and federal funding shift toward New Approach Methodologies (NAMs).
FDA Modernization Act 2.0
President Biden signs legislation ending the requirement for animal testing for new drug protocols.
EU Cosmetics Ban
The European Union implements a full ban on the sale of animal-tested cosmetics.
The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Three infants in three states were diagnosed with botulism after consuming Nara Organics powdered formula, prompting a voluntary recall of all whole milk formula. All babies recovered, but the FDA and CDC investigation highlights risks of powdered formula for newborns and emphasizes clinical vigilance among pediatricians.
A cluster of three infant botulism cases, despite zero positive C. botulinum tests in product lots, has forced Nara Organics to recall all whole milk powdered formula. The incident raises critical quality control and sterility challenges for the organic infant nutrition sector.
Global regulators are accelerating the transition toward non-animal testing methods in drug development, yet a significant innovation gap remains. While the FDA and EU have eased mandates, current AI and organ-on-a-chip technologies cannot yet fully replicate the systemic complexity of living organisms.